This study was to test safety and efficacy of 1:1 mixture of gadolinium:nonionic contrast media in avoiding contrast nephropathy during coronary angiography in patients with renal dysfunction. Although "off label" for x-ray angiography, gadolinium has drawn attention for its potential to avoid contrast nephropathy during coronary angiography. Initial data seem promising. Patients with a baseline creatinine of 1.5 mg/dl or more were included. In order to minimize contrast nephropathy risk, all patients were thoroughly hydrated and treated by N-acetylcysteine. After coronary angiography and/or percutaneous coronary intervention, renal function tests were remeasured on days 1, 2, and 3. A rise of 0.5 mg/dl or more in creatinine value in the following 3 days or the need for dialysis were considered as a contrast nephropathy event. Twenty-six patients were enrolled in this study. Ten were women and 16 were men. The mean age was 65.7 ± 11. Baseline creatinine value was 2.47 ± 0.74 mg/dl. The total amount of contrast medium used on 1:1 fashion was 57.1 ± 27.2 ml. No procedure-related cardiac complication or contrast nephropathy event occurred in this study. Although there was a slight loss in image quality, we felt that the results were adequate for interpretation. Although "off label," using gadolinium contrast media in a 1:1 mixture with standard nonionic low osmolar contrast media seems to be a viable option in decreasing the likelihood of contrast nephropathy. Further evaluation appears to be warranted.
Introduction
Despite 40 years of experience, radiocontrastinduced nephropathy (RCIN) is an unresolved issue. Implications of RCIN may be disastrous, with an in-hospital mortality rate of 20% in nonemergency patients. [1] [2] [3] The incidence of RCIN depends on a number of factors: preexisting renal insufficiency (most significant), diabetes, congestive heart failure, volume depletion, and dose of contrast agent. 4, 5 Thus far, the only consistently proven effective interventions to avoid RCIN among high-risk patients are vigorous hydration and the use of low osmolar and nonionic agents instead of high osmolar contrast media at the lowest possible dose. 6, 7 Gadolinium chelates are used for magnetic resonance imaging. They are proposed to have no adverse effects on renal function within recommended doses up to 0.3 to 0.4 mmol/kg. 8, 9 Because it appears to have very little nephrotoxic effect as a contrast agent, several articles related with gadolinium chelates (although "off label") have been published in imaging different vascular territories during digital substraction angiography (DSA) or coronary angiography in patients with moderate to severe renal dysfunction. [10] [11] [12] [13] In these reports, gadolinium chelates have been used as the sole agent, 10 in conjunction with carbon dioxide 11 or nonionic low osmolar contrast media 12 with adequate image quality and almost no nephrotoxicity.
Methods
In order to evaluate the potential benefit of gadolinium as a contrast medium during coronary angiography in patients with renal dysfunction, we performed this study. Twenty-six patients with a baseline serum creatinine of 1.5 mg/dl or more, referred for coronary angiography, were consecutively included in this study. We used gadopentetate dimeglumine-based contrast material (0.5 mol/L; Magnevist, Schering, Berlin, Germany) and a low osmolar nonionic contrast agent (Iohexol, Omnipaque; Nycomed, Cork, Ireland) on a 1:1 basis. Written informed consent was obtained from all individuals.
To minimize renal injury, all patients had intravenous saline hydration 1 ml/kg/h for 12 hours before and after the procedure. Patients were also motivated for liberal fluid intake 1 day before, on the day of the procedure, and afterward. Because of supportive evidence, 14 patients were given oral acetylcysteine 1200 mg daily before the day, on the day, and on the day after the procedure as part of a routine practice for patients with a baseline creatinine value of 1.3 mg/dl or more in our institution. Renal function was assessed before the procedure and on a daily basis during the following 3 days using serum creatinine, urea, sodium, potassium, and creatinine clearance. The Cockcroft-Gault formula 15 was used to estimate creatinine clearance. An increase of 0.5 mg/dl of creatinine value in 72 hours of follow-up or the need for dialysis during hospitalization period were considered to reflect an RCIN event for research purposes. The total amount of contrast used on average (1:1 fashion) was 57.1 ± 27.2 ml. Because we did not have a biplane imaging facility in our institution, all studies were performed with monoplane systems. Renal function data are presented in Table I .
Statistical Analysis
Statistical analysis was performed using an SPSS 10.0 computer program. Continuous variables are presented as mean ± standard deviation. To compare precoronary and postcoronary angiography values, we used the paired t test. A P value of less than .05 was considered significant.
Results
There were 10 women and 16 men. The mean age was 65.7 ± 11 years. Ten patients were diabetic (38%), 2 patients had compensated heart failure (8%), and 22 patients had history of hypertension (85%). Mean baseline serum creatinine was 2.47 ± 0.74 mg/dl. Two of the patients had staged coronary angiography and percutaneous coronary intervention (PCI). Five had a PCI extended to a coronary angiography, and 10 patients were recommended bypass surgery. Clinical characteristics and cardiovascular background are given in Table II , and the changes in creatinine value with respect to days are given in Figure 1 .
Coronary angiography and, where necessary, PCI were successfully performed in all cases. Although we saw a slight loss of image quality, we felt that the results were satisfactory enough to reach diagnostic conclusions and perform subsequent therapeutic interventions.
Because baseline renal dysfunction was moderate to severe, every attempt was made to limit the total amount of the contrast media.
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None of the patients in this study had an RCIN event. Interestingly, renal functions slightly but statistically significantly improved. Similar findings were reported by Rieger et al. 11 The most likely explanation for this effect seems to be vigorous hydration.
Discussion
Gadolinium, although used for magnetic resonance imaging studies, is an attractive agent for "off-label" DSA and coronary angiography studies in patients with moderate to severe renal insufficiency. There are several case reports, small series, and larger retrospective analyses indicating no or minimal nephrotoxicity of gadolinium in patients with moderate to severe renal dysfunction; however, there are some limitations of using gadolinium other than being "off label." During coronary angiography, because the maximum recommended dose is 0.3 to 0.4 mmol/kg or 0.6 to 0.8 ml/kg, in many instances, there would be a need for an excess of the maximum recommended dose. For example, in an averaged-sized adult of 70 kg, 40 to 55 ml of gadolinium are in the recommended range, and this amount may not be enough for many patients, especially if the procedure would be extended with a PCI. In this context, it may be prudent to use gadolinium with a nonionic contrast so as to be able to increase the total amount of contrast media without increasing the risk of gadolinium-related toxicity and cost.
Another issue is image quality. Although there is some loss of image quality (especially when gadolinium is the sole agent), our experience and the experience of others are in parallel that satisfactory enough results could be achieved, especially with a mixture gadolinium and nonionic contrast media. 12 In a recent optical-density DSA study, the gadolinium-iodinated media mixture was documented by way of a phantom study to be visualized markedly better than gadolinium only. 16 Cost is another important issue. Generally, gadolinium chelates are approximately 5 times more expensive than nonionic low osmolar contrast media in many countries. In a very similar group of patients (with respect to renal function and total contrast media used), Sarkis et al 12 demonstrated efficacy and safety of 2:1 gadolinium:nonionic low osmolar contrast media coronary angiography. Our data confirm and further extend contrast nephropathy literature in terms of efficacy and safety of gadolinium/nonionic low osmolar contrast mixture in performing coronary angiography/PCI. On a one-to-one basis of gadolinium:nonionic low osmolar contrast media will be less costly. Possibly, avoidance of contrast nephropathy occurrence would also help to decrease the total cost.
To the best of our knowledge, there is no head-to-head comparison of nonionic low osmolar contrast media and gadolinium-based Creatinine levels (mg/dL) 3 (sole agent or in mixture) coronary angiography or other x-ray examination in terms of the prevalence of contrast nephropathy. Because gadolinium for x-ray examinations is "off label," such a study may never be performed.
We must admit that without a well-matched control group of nonionic low osmolar contrast media with similar baseline renal function, clinical characteristics, and total amount of contrast volume, one might simply explain the issue with vigorous hydration protocol and low amount of total contrast volume used. It is difficult to bring a strong argument against this point of view; however, this limitation seems evident in other gadolinium-x-ray angiographycontrast nephropathy literature. [11] [12] [13] On the other hand, the group of patients studied have really poor renal function (with an average creatinine of 2.47 mg/dl and an average creatinine clearance value of 30 ml/min), and in such patients, it is not uncommon to experience RCIN despite all efforts. We think, with our study, we can state that using low amounts of 1:1 mixture of gadolinium:nonionic low osmolar contrast media is effective and safe in avoiding contrast nephropathy in patients with moderate to severe renal dysfunction during coronary angiography. Our study supports the growing notion that gadolinium may have a role in avoiding contrast nephropathy during coronary angiography.
Conclusion
In summary, we conclude that coronary angiography/PCI with a 1:1 mixture of gadopentetate dimeglumine:nonionic low osmolar contrast media added to well hydration and N-acetylcysteine treatment is a safe, efficacious procedure for avoiding RCIN in patients with moderate to severe renal dysfunction. Given the increasing number of efficacy and safety data, authorities may possibly re-evaluate gadolinium chelates as an x-ray contrast media in renal failure patients.
